E. Serra‐Baldrich
YOU?
Author Swipe
View article: Anogenital Contact Dermatitis in Spain: A <scp>REIDAC</scp> Study of Patients Undergoing Patch Testing in 2019–2024
Anogenital Contact Dermatitis in Spain: A <span>REIDAC</span> Study of Patients Undergoing Patch Testing in 2019–2024 Open
Background The REIDAC (Spanish Registry for Research in Contact Dermatitis) conducts nationwide epidemiological surveillance of contact dermatitis in Spain. Anogenital involvement within REIDAC has not been previously studied. Objectives T…
View article: [Translated article] Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) Still be Part of the Baseline Series?
[Translated article] Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) Still be Part of the Baseline Series? Open
Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish b…
View article: Vaccination Recommendations in Patients With Atopic Dermatitis Treated With <scp>JAK</scp> Inhibitors
Vaccination Recommendations in Patients With Atopic Dermatitis Treated With <span>JAK</span> Inhibitors Open
Atopic dermatitis therapy has undergone a revolutionary change with the introduction of Janus kinase (JAK) inhibitors. Despite their general safety profile, these immunomodulatory drugs require special precautions with respect to infection…
View article: Patient Burden And Impact Of Moderate-to-Severe Atopic Dermatitis In the Spanish Healthcare System: The APOLO Cross-Sectional Study
Patient Burden And Impact Of Moderate-to-Severe Atopic Dermatitis In the Spanish Healthcare System: The APOLO Cross-Sectional Study Open
Introduction: Atopic dermatitis (AD) is an inflammatory chronic condition associated with a significant physical, psychological, and economic burden. Objective: This study aims to determine the multidimensional impact of atopic dermatitis …
View article: Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials
Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials Open
Introduction: Lebrikizumab significantly reduced itch and itch interference on sleep in patients with moderate-to-severe atopic dermatitis (AD) at week 16 in two phase 3 trials. We investigated itch reduction and the efficacy of improving …
View article: European Guideline (<scp>EuroGuiDerm</scp>) on atopic eczema: Living update
European Guideline (<span>EuroGuiDerm</span>) on atopic eczema: Living update Open
The evidence‐ and consensus‐based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in…
View article: Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis on the Genitals: Interim Data on Improvements in Physician-Assessed Disease Severity and Patient-Reported Outcomes in up to 3 Months of Treatment in the TRACE Study
Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis on the Genitals: Interim Data on Improvements in Physician-Assessed Disease Severity and Patient-Reported Outcomes in up to 3 Months of Treatment in the TRACE Study Open
Introduction: Atopic dermatitis (AD) can involve any part of the skin, including the genital region. Presentation of AD on genitals is often overlooked/underreported due to reluctance to discuss this sensitive area with clinicians and lack…
View article: Advances in Atopic Dermatitis and Chronic Hand Eczema: Delgocitinib and Tralokinumab
Advances in Atopic Dermatitis and Chronic Hand Eczema: Delgocitinib and Tralokinumab Open
This article summarizes selected poster presentations from the 2024 Fall Clinical Dermatology Conference (FCDC), with a focus on updated data for tralokinumab in atopic dermatitis (AD) and delgocitinib cream in chronic hand eczema (CHE), a…
View article: Defining the Care Pathway in Patients with Psoriasis and Atopic Dermatitis
Defining the Care Pathway in Patients with Psoriasis and Atopic Dermatitis Open
The findings underscore the necessity for interventions to reduce wait times and improve treatment immediacy and effectiveness post-diagnosis. The insights from this study can direct enhancements in patient management and satisfaction for …
View article: Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023
Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023 Open
Introduction Patch test results may be influenced by age‐related factors. However, there is still discordant evidence between age and patch test results. Objectives We aim to evaluate the patch test results reflecting skin sensitisation, t…
View article: An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1)
An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1) Open
Background Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione. Objective To evaluate a case series of ACD to PE in Spain. M…
View article: A re‐assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight
A re‐assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight Open
Background Budesonide and tixocortol pivalate as markers of contact allergy to corticosteroids have been questioned, as they are not able to detect a significant percentage of allergic patients. Objectives To investigate the potential role…
View article: Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study
Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study Open
Background Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real‐world data on its efficacy and safety in treating moderate‐to‐severe atopic dermatitis (AD) remains limited. Objectives This s…
View article: Chronic nodular prurigo: Association between comorbidities, itch and quality of life
Chronic nodular prurigo: Association between comorbidities, itch and quality of life Open
International audience
View article: EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions
EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions Open
Chronic pruritus (CP) is frequent in general medicine and the most common complaint in general dermatology. The prevalence of CP is expected to rise in the future due to the ageing population. The clinical presentation, underlying aetiolog…
View article: Italian S3-Guideline on the treatment of Atopic Eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)
Italian S3-Guideline on the treatment of Atopic Eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA) Open
The evidence- and consensus-based guideline on atopic eczema, published in JEADV on 18 August 2022 (part 1) and 3 September 2022 (part 2) was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual…
View article: Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)
Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA) Open
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permis…
View article: Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)
Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA) Open
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permis…
View article: [Translated article] Epidemiological, Clinical, and Allergic Profile of Psoriatic Patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC)
[Translated article] Epidemiological, Clinical, and Allergic Profile of Psoriatic Patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC) Open
Overall, 36.2% of psoriatic patients tested positive in PT to the 2022 Spanish battery of allergens, which proved that this association is not uncommon. Overall, psoriatic patients had a higher mean age, were more predominantly men, and sh…
View article: Sensitization to textile dyes in Spain: Epidemiological situation (2019–2022)
Sensitization to textile dyes in Spain: Epidemiological situation (2019–2022) Open
Background Current frequency and features for positivity to textile dye mix (TDM) in Spain are unknown. Objectives To study the frequency, clinical features and simultaneous positivity between TDM, para‐phenylenediamine (PPD) and specific …
View article: <scp>2‐Hydroxyethyl</scp> methacrylate (<scp>2‐HEMA</scp>) sensitization, a global epidemic at its peak in Spain?
<span>2‐Hydroxyethyl</span> methacrylate (<span>2‐HEMA</span>) sensitization, a global epidemic at its peak in Spain? Open
Background A global epidemic of allergic contact dermatitis to (meth)acrylates has been described in relation to the widespread use of manicure products. Objectives To evaluate the frequency of sensitization to 2‐hydroxyethyl methacrylate …